Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489096 | 1.00 | PTGS2 (0.68) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2489099 | 1.00 | PTGS2 (0.68) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17686269 | 1.00 | PTGS2 (0.68) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2486356 | 0.95 | PTGS2 (0.72) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17351189 | 0.95 | PTGS2 (0.72) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2493085 | 0.95 | PTGS2 (0.72) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17351188 | 0.95 | PTGS2 (0.72) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2490051 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2490050 | 0.92 | PTGS2 (0.67) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL17686264 | 0.91 | PTGS2 (0.66) | PTGS2PTGS1HRH4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, PTGES2, ALOX5 | PTGS2 7/4885PTGS1 4/4885HRH4 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.